Skip to main content

Advertisement

Figure 5 | Molecular Cancer

Figure 5

From: Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia

Figure 5

Effects of Vav3 siRNA (si-Vav3) and docetaxel (DTX) on xenograft tumor growth. LNCaPH cells implanted subcutaneously into nude mice and treated with si-Vav3 and/or DTX. A, dose–response curves of si-Scr and si-Vav3. Changes in the tumor volume were followed over time. The initial tumor volume (n = 8) was considered as 100%, and the average tumor volumes are expressed as percentages of the average initial tumor volume of each group on day 21 after LNCaPH cell inoculation. Values represent the mean ± SE. Asterisk indicates P <0.05 compared with the findings in control tumors. Arrows indicate treatment days. B , in vivo combination study in LNCaPH bearing nude mice. Change in the tumor volume was followed over time. The initial tumor volume (n = 8) was considered as 100%, and the average tumor volumes are expressed as percentages of the average initial tumor volume of each group on day 21 after LNCaPH cell inoculation. Values represent the mean ± SE. Asterisk indicates P <0.05 compared with the findings in control tumors. Arrows indicate treatment days. C , immunoblot analysis of Vav3 in control, si-Scr-treated, and si-Vav3-treated tumors was performed using an anti-Vav3 antibody. Blots were stripped and reprobed with an antibody against β-tubulin. D, representative H&E staining (100× magnification) and immunohistochemical analysis of Vav3, Ki-67, pAR, and M30 CytoDeath in xenograft tumor specimens (200× magnification ). E, data table lists the mean ± SE for four groups.

Back to article page